$MEDS Is Loaded for a Short Squeeze: The FINRA Numbers Say $1.40 Is in Play
Short volume is a clue, not a confession. My read on what it does and doesn't say about DataMEDS AI.

Listen: hear this article read aloud (about 2 min).
Somebody is still shorting DataMEDS AI into this, and the FINRA data doesn't care about anyone's opinion. It counts.
$MEDS sits at $1.23, $1.06 below its 20-day high of $2.29 and $0.74 above its 20-day low of $0.4925.
My read: lean bullish. Buyers are close enough to force the issue, but I want volume before I call it a breakout.
Pressing into strength
Against its own 60-session range, $MEDS is 90.0% below the high of $12.31 (Sep 16) and 149.7% above the low of $0.4925 (Nov 16). $MEDS closed higher in 3 of its last 9 sessions.
Volume over the last five sessions averaged 13.8x the twenty sessions before them.
The largest one-day move in the past twenty sessions was +34.7% on Nov 20. 50% of MEDS's off-exchange volume printed as short sales (FINRA daily short volume). The stock is already running, and the run has gone parabolic: shorts are losing, not waiting.
What I make of it: a crowded short matters only if the stock stops falling, and then covering becomes buying. Whether that starts here is the whole question.
What the market looks to be pricing in
Off-exchange trading: NORMAL: $36K block at $1.02, high off-exchange share. Biggest single off-exchange print: 35,642 shares at $1.02, about $36K, on a downtick (seller hit). A print that size is one order being crossed away from the public book, not a crowd of small trades.
Squeeze risk 0 of 100; shorts pressing 63 of 100. Across the broader market, the read is Lean bearish (bias -33). Insiders: quiet.
On the daily chart, technical patterns include outside_bar, bearish_belt_hold, inside_bar in a down trend.
Price is below its 20-day average of $1.30 by 5.7%.
What I make of it: the pieces mostly point the same way as the price, which is more than I can say for most setups. None of them is proof.
The bull case
- Short squeeze setup with a measured path to $1.40
The bear case
- Backdrop: Lean bearish (bias -33)
- Borrow cost decides who exits first
The part nobody is talking about
What I think traders are overlooking is how little room the thesis needs. The line that proves it wrong is close and the level it points to is not, which is the kind of imbalance I like to see.
The price alone doesn't show it.
If I'm right, and what proves me wrong
If $MEDS posts a close above the recent high on rising volume and volume expands, I think $1.40 becomes the next serious test. Under $1.11, I'm wrong.
The honest objection is that short volume is not a short position. A high ratio is routine in liquid names, and sometimes the shorts are simply right.
That's the whole trade: a level to clear, a line that proves me wrong, and not much in between.
Kill switch
Any one of these and the thesis is over, no averaging down, no renaming it.
- A close through $1.11.
- Selling absorbs the buying at a key level and price loses it on volume.
- Order flow reverses: the sweeps and blocks turn to the other side.
- A scheduled event changes the picture before the trigger is reached.
What I'm watching
Buyers are close enough to force the issue. I want the volume before I call it anything more than a lean.
Desk record. 50 of 327 scenario targets traded before their invalidation (15%), 201 stopped out, 76 ran out of time, average outcome -1.21% per piece. Past pieces say nothing about this one.
The desk's scenario leans bullish. Bull or bear, the kill switch above is what keeps either view honest.
Sources and further reading: SEC EDGAR filings for MEDS · FINRA daily short sale volume files · Nasdaq short interest: MEDS · MEDS quote, chart and data on StockMarketLoop.
Data as of Nov 20, 9:43 AM ET: options positioning, FINRA short volume, the off-exchange trade record, the structure map, SEC filings and the ticker's headlines. Vaughn McNair (Grandmaster-Obi) and Making Easy Money may hold or trade positions in the names discussed. This is speculation and education, not financial advice.

Sign up now to get access to the library of members-only issues.
Free. Confirm by email. One click to leave.
Discussion (0)